Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target ...

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases ...

Outside of Empaveli and Syfovre, Apellis also has a growing pipeline of complement therapeutics focused on rare disease and ...

Amin covers the Healthcare sector, focusing on stocks such as Ocular Therapeutix, Apellis Pharmaceuticals, and BridgeBio Pharma. The word on The Street in general, suggests a Strong Buy analyst ...

Apellis' chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may have been heightened by new follow-up data from two ...

Overall, Apellis reported total third-quarter revenues of $196.8 million, up 78% year over year. Beyond Syfovre, the company’s paroxysmal nocturnal hemoglobinuria drug Empaveli grew sales 0.4% ...

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...

Peer Ratings Comparison In this comparison, we explore the analyst ratings and average 1-year price targets of Iovance Biotherapeutics, Apellis Pharmaceuticals and Amicus Therapeutics, three ...

The company is also involved in several research collaborations with pharmaceutical giants such as Pfizer Inc., Apellis Pharmaceuticals, Verve Therapeutics, Inc., Sana Biotechnology, Inc., and ...